Biodistribution, pharmacokinetics, and nuclear imaging studies of 111in-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma

Molecular Imaging and Biology

Volumn 13, Issue 4, 2011, Pages 721-729

  Wen, Xiaoxia ^a   Lyu, Mi Ae ^a   Zhang, Rui ^a   Lu, Wei ^a   Huang, Qian ^a   Liang, Dong ^b   Rosenblum, Michael G ^a   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS SOUTHERN UNIVERSITY   (United States)

Author keywords

B cell lymphoma; Biodistribution; Cytokine blymphocyte stimulator; Gamma imaging; Gelonin; Pharmacokinetics

Indexed keywords

B CELL ACTIVATING FACTOR; GELONIN; GELONIN B LYMPHOCYTE STIMULATOR FUSION PROTEIN PENTETIC ACID IN 111; PENTETIC ACID; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER CELL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; EX VIVO STUDY; FEMALE; IMAGE ANALYSIS; IN VITRO STUDY; ISOTOPE LABELING; MALE; MANTLE CELL LYMPHOMA; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; B-CELL ACTIVATING FACTOR; CELL DEATH; CELL LINE, TUMOR; CHROMATOGRAPHY, THIN LAYER; FEMALE; HUMANS; INDIUM RADIOISOTOPES; INJECTIONS, INTRAVENOUS; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, SCID; PENTETIC ACID; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; STAINING AND LABELING; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

MUS;

EID: 80052633325     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0391-0     Document Type: Article

References (30)

1. Do RKG, Hatada E, Lee H et al (2000) Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 192:953-964
2. Moore PA, Belvedere O, Orr A et al (1999) BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-263 (Pubitemid 29330000)
3. 2-terminal kinase. J Biol Chem 274:15978-15981
4. Schneider P, MacKay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756 (Pubitemid 29272691)
5. Shu HB, Hu WH, Johnson H (1999) TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 65:680-683 (Pubitemid 29227061)
6. Tribouley C, Wallroth M, Chan V et al (2005) Characterization of a new member of the TNF family expressed on antigen presenting cells. Biol Chem 380:1443-1447
7. Thompson JS, Bixler SA, Qian F et al (2001) BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293:2108-2111 (Pubitemid 32848062)
8. von Bulow G-U, Bram RJ (1997) NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 278:138-141 (Pubitemid 27446295)
9. Laabi Y, Gras MP, Carbonnel F et al (1992) A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J 11:3897-3904
10. Thompson JS, Schneider P, Kalled SL et al (2000) BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 192:129-136
11. Gross JA, Johnston J, Mudri S et al (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999 (Pubitemid 30243593)
12. Javier B, John MT, David MH, Ronald L (2002) BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 30:135-141
13. MA BA, Hewitt J et al (2004) Tumor targeting, dosimetry and clinical response data for lymphorad-131 (LR131; I-131 labeled B-lymphocyte stimulator) in patients with relapsed/refractory non-Hodgkin's lymphoma. Blood 104:241a
14. Stirpe F, Olsnes S, Pihl A (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 255:6947-6953 (Pubitemid 11234436)
15. Sperti S, Brigotti M, Zamboni M, Carnicelli D, Montanaro L (1991) Requirements for the inactivation of ribosomes by gelonin. Biochem J 277:281-284
16. Veenendaal LM, Jin H, Ran S et al (2002) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99:7866-7871 (Pubitemid 34650971)
17. CD BM, Sperti S, Montanaro L (1994) RNA present in post-ribosomal supernatants makes ribosomes susceptible to inactivation by gelonin and alpha-sarcin. Biochem Mol Biol Int 32:585-596 (Pubitemid 24092554)
18. Rosenblum MG, Cheung LH, Liu Y, Marks JW III (2003) Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 63:3995-4002 (Pubitemid 36917918)
19. Rosenblum MG, Shawver LK, Marks JW et al (1999) Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models. Clin Cancer Res 5:865-874 (Pubitemid 29180839)
20. MJ RMG, Cheung L, Rifkin R, Salmon S, Bartholomew R (1991) A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin. Mol Biother 3:6-13
21. Duzkale H, Pagliaro LC, Rosenblum MG et al (2003) Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 9:364-372 (Pubitemid 38351807)
22. Lyu M-A, Cheung LH, Hittelman WN et al (2007) The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6:460-470 (Pubitemid 46332448)
23. Nimmanapalli R, Lyu M-A, Du M et al (2007) The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 109:2557-2564 (Pubitemid 46425902)
24. Riccobene TA, Miceli RC, Lincoln C et al (2003) Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice. J Nucl Med 44:422-433 (Pubitemid 39586020)
25. Marathe PH, Shyu WC, Humphreys WG (2004) The use of radiolabeled compounds for ADME studies in discovery and exploratory development. Curr Pharm Des 10:2991-3008 (Pubitemid 39214007)
26. Pavlinkova G, Beresford GW, Booth BJM, Batra SK, Colcher D (1999) Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of mAb CC49 in colon carcinoma xenografts. J Nucl Med 40:1536-1546 (Pubitemid 29428939)
27. Oren DA, Li Y, Volovik Y et al (2002) Structural basis of BLyS receptor recognition. Nature Struct Mol Biol 9:288-292 (Pubitemid 34289902)
28. Hsu AR, Cai W, Veeravagu A et al (2007) Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J Nucl Med 48:445-454 (Pubitemid 47604931)
29. Buchsbaum DJ, Sinkule JA, Stites MS et al (1988) Localization and imaging with radioiodine-labeled monoclonal antibodies in a xenogeneic tumor model for human B-cell lymphoma. Cancer Res 48:2475-2482
30. Lyu M-A, Rai D, Ahn KS et al. 2010. The rGel/BLys fusion toxin inhibits diffuse largeBcell lymphoma growth in vitro and in vivo.Neoplasia 12:366-375